Amgen Expands Cancer Portfolio with Up to $840M Dark Blue Therapeutics Deal
The acquisition, valued at up to $840 million, strengthens Amgen's oncology pipeline with a drug candidate addressing challenging leukemia markers, signaling commitment to hematologic cancers.
Acquisition Details
- Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million, targeting a new cancer therapy.
- The focus is on a small-molecule degrader that acts on MLLT1 and MLLT3 proteins, potential drivers of acute myeloid leukemia (AML).
Strategic Rationale
- AML remains an area of high unmet medical need; this asset could complement Amgen’s existing cancer treatments.
- The acquisition reflects ongoing investments by big pharma into innovative targeted therapies for blood cancers.
Outlook
- Clinical development and regulatory review will determine the candidate's future success, with early data closely watched by investors and clinicians.
More details available at BioSpace.
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.